Main Menu

ICR-CTSU clinical trials

The ICR-CTSU manages a number of trials in different disease sites. Use the filter below to view trials for each cancer type:


Open to recruitment


International penile advanced cancer trial  - an International Rare Cancers Initiative study.


International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer.


A phase II/III trial of Primary radiothErapy for Androgen sensitive pRostate cancer patients with Lymph nodeS.


A Randomised phase II trial of Enhancement of efficacy of Atezolizumab by Radiotherapy in Metastatic urothelial carcinoma.


A randomised phase III trial comparing conventional dose chemotherapy using paclitaxel, ifosfamide and cisplatin (TIP) with high dose chemotherapy using mobilising paclitaxel plus ifosfamide followed by high dose carboplatin and etoposide (TI-CE) as first treatment in relapsed or refractory germ cell tumours.

In follow-up

111 trial

Single group trial evaluating one cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy in high risk, stage 1 non seminomatous germ cell tumours of the testis.


Phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomy.


Randomised phase II study of radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer.


Randomised phase III placebo controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder.


Phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.


Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.


A multicentre, randomised phase II study of hypofractionated bladder radiotherapy with or without image guided adaptive planning.


Randomised controlled trial of laparoscopic, open and robot assisted prostatectomy as treatment for organ confined prostate cancer.


Randomised phase II trial of prostate and pelvis versus prostate alone treatment for locally advanced prostate cancer.


Phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer.


Prospective randomised phase III study of observation versus screening MRI and pre-emptive treatment in castrate resistant prostate cancer patients with spinal metastasis.


Randomised phase II trial of adaptive image guided standard or dose escalated tumour boost radiotherapy in the treatment of transitional cell carcinoma of the bladder.


Randomised phase II study of enzalutamide (MDV3100) in combination with AZD5363 in patients with metastatic castration resistant prostate cancer.


Phase II open label study of biomarkers to assess response in patients with metastatic castration-resistant prostate cancer treated with radium-223.


Randomised trial of selective bladder preservation against radical excision (cystectomy) in muscle invasive T2/T3 transitional cell carcinoma of the bladder – feasibility study.


Phase II trial of olaparib in patients with advanced castration resistant prostate cancer.



Intercontinental is an international phase III randomised trial comparing intermittent versus continuous androgen suppression for patients with prostate-specific-antigen progression in the clinical absence of distant metastases following radiotherapy for prostate cancer.

Penile TPF

Phase II trial of docetaxel, cisplatin and 5-fluorouracil chemotherapy (TPF) in locally advanced and metastatic carcinoma of the penis.


A Pilot Study for a Phase III Clinical Trial in Patients with Favourable Risk Prostate Cancer Comparing Active Surveillance Therapy Against Radical Treatment


Phase II trial of vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis.

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.

Current vacancies